Ligand Pharmaceuticals | LGND - Cost Of Sales


Ligand Pharmaceuticals reported $11.31M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
Agenus USD 642K 399K Sep/2025
Amgen USD 1.87B 271M Jun/2026
Anika Therapeutics USD 11.44M 797K Dec/2025
Baxter International USD 1.93B 118M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Eli Lilly USD 3.27B 309M Jun/2026
Enviri Corporation USD 472M 17.65M Dec/2025
Gilead Sciences USD 1000M 445M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Glaxosmithkline GBP 1.88B 1.6B Mar/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Insmed USD 69.29M 19.79M Jun/2026
Intrexon USD 1.01M 344K Jun/2024
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
Ligand Pharmaceuticals USD 11.31M 59K Jun/2026
MacroGenics USD 9.53M 585K Mar/2026
Merck USD 3.14B 200M Jun/2026
Pacira USD 58.49M 7.75M Jun/2026
Pfizer USD 4.09B 498M Jun/2026
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Veracyte USD 42.19M 3.7M Jun/2026